Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response With Alternate-Day vs Daily Lenalidomide vs No Maintenance After Autologous Stem Cell Transplant in Multiple Myeloma
TCTR20250326004Phase 4Not yet recruiting
- Sponsor
- Mahidol University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lenalidomide in multiple myeloma (MM) (3 arms), sponsored by Mahidol University. Primary endpoint: Immune response comparison. Planned start May 2025; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on TCTR20250326004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250326004.